Sorrento Therapeutics, Inc. has signed a non-exclusive research license agreement providing access to Lonza’s GS Xceed Gene Expression System for the generation of stable expression cell lines for the production and development of therapeutic antibodies.   Sorrento will use the GS technology for its maturing pipeline of therapeutic antibodies in oncology, inflammation, and infectious disease, including the production of antibodies targeting the vascular epidermal growth factor receptor 2 (VEGFR2...